AGEN1721 / Agenus - LARVOL DELTA

AGEN1721, a first-in-class Fc-enhanced bifunctional antibody targeting FAP and TGFβ, remodels the tumor microenvironment to overcome cancer-associated fibroblast-mediated immune suppression (SITC 2024) - "Ethics Approval This study obtained ethics approval for animal studies. IUCAC protocol numbers NLS18-016 and NLS21-015."

Biomarker • IO biomarker • Tumor microenvironment • Breast Cancer • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • CAFs • CD8 • FAP • TGFB1 • TGFBR2

Agenus to Present Compelling Data on…AGEN1721 at SITC 2024 (Businesswire) - "An additional presentation will cover AGEN1721, a first-in-class, Fc-enhanced bifunctional antibody targeting FAP and TGFβ. AGEN1721 is engineered to remodel the tumor microenvironment by depleting cancer-associated fibroblasts (CAFs) and neutralizing TGFβ’s immunosuppressive effects. By facilitating T-cell infiltration and activation, AGEN1721 effectively transforms cold tumors into 'hot,' immune-responsive environments."

Preclinical • Oncology • Solid Tumor